HIV news from aidsmap.com

Switching to an integrase inhibitor can raise diabetes risk in people with HIV
Two large studies have found that switching to an integrase inhibitor carries a moderately increased risk of developing type 2 diabetes for some groups of people with HIV. In one study, which combined data from 27 cohorts of people receiving HIV care in North America, switching from a protease inhibitor to an integrase inhibitor increased the risk of developing type 2 diabetes within two years. Switching from a non-nucleoside reverse transcriptase inhibitor to an integrase inhibitor did not raise the risk of developing diabetes.
>> Read more

Bepirovirsen leads to functional cure in one fifth of people with long-term hepatitis B
One in five people with chronic (long term) hepatitis B who were treated with the investigational agent bepirovirsen were functionally cured and no longer needed to take daily antiviral therapy, according to late-stage study results presented last week at the European Association for the Study of the Liver (EASL) Congress in Barcelona and published in The New England Journal of Medicine.
>> Read more

Injectable PrEP in Leeds and London: criteria, approval and continuation
In February this year, the UK government announced that it was expanding NHS England’s initial rollout of long-acting injectable HIV PrEP to 2000 people rather than the 1000 it initially announced last November.
>> Read more